These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

698 related articles for article (PubMed ID: 34002056)

  • 1. Kinase drug discovery 20 years after imatinib: progress and future directions.
    Cohen P; Cross D; Jänne PA
    Nat Rev Drug Discov; 2021 Jul; 20(7):551-569. PubMed ID: 34002056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
    Tsubaki M
    Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
    Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
    Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed resistance to imatinib after 16 years of therapy in a patient with chronic myeloid leukaemia.
    Kaur U; Gambhir IS; Khare VR; Singh A; Chakrabarti SS
    Br J Haematol; 2020 Jul; 190(1):e51-e53. PubMed ID: 32400888
    [No Abstract]   [Full Text] [Related]  

  • 5. Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval.
    Goggin C; Stansfeld A; Mahalingam P; Thway K; Smith MJ; Huang P; Jones RL; Napolitano A
    Future Oncol; 2022 Aug; 18(26):2967-2978. PubMed ID: 35880452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib.
    Di Vito A; Ravegnini G; Gorini F; Aasen T; Serrano C; Benuzzi E; Coschina E; Monesmith S; Morroni F; Angelini S; Hrelia P
    Pharmacol Ther; 2023 Aug; 248():108475. PubMed ID: 37302758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.
    Serrano C; George S; Valverde C; Olivares D; García-Valverde A; Suárez C; Morales-Barrera R; Carles J
    Target Oncol; 2017 Jun; 12(3):277-288. PubMed ID: 28478525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current status and progress in novel drug research for gastrointestinal stromal tumors].
    Dong Z; Li J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):911-916. PubMed ID: 32927518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.
    Losson H; Gajulapalli SR; Lernoux M; Lee JY; Mazumder A; Gérard D; Seidel C; Hahn H; Christov C; Dicato M; Kirsch G; Han BW; Schnekenburger M; Diederich M
    Pharmacol Res; 2020 Oct; 160():105058. PubMed ID: 32619722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next questions for the medical treatment of gastrointestinal stromal tumor.
    Italiano A
    Curr Opin Oncol; 2022 Jul; 34(4):348-353. PubMed ID: 35730519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-(Imidazo[1,2-a]pyridin-3-yl): pyrimidine derivatives as anticancer agents.
    Al-Horani RA
    Pharm Pat Anal; 2023 Jan; 12(1):13-18. PubMed ID: 36354042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib.
    Ottmann O; Saglio G; Apperley JF; Arthur C; Bullorsky E; Charbonnier A; Dipersio JF; Kantarjian H; Khoury HJ; Kim DW; Healey D; Strauss L; Cortes JE
    Blood Cancer J; 2018 Sep; 8(9):88. PubMed ID: 30190469
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative study of the anti-leukemic effects of imatinib mesylate, Glivec™ tablet and its generic formulation, OHK9511.
    Yokoo M; Kubota Y; Tabe Y; Kimura S
    Biol Pharm Bull; 2015; 38(3):411-6. PubMed ID: 25757922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in kinase drug discovery: targets, indications and inhibitor design.
    Attwood MM; Fabbro D; Sokolov AV; Knapp S; Schiöth HB
    Nat Rev Drug Discov; 2021 Nov; 20(11):839-861. PubMed ID: 34354255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanding spectrum of anticancer drug, imatinib, in the disorders affecting brain and spinal cord.
    Kumar M; Kulshrestha R; Singh N; Jaggi AS
    Pharmacol Res; 2019 May; 143():86-96. PubMed ID: 30902661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nilotinib monotherapy induced complete remission in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to imatinib and dasatinib.
    Sekimizu M; Yamashita Y; Ueki H; Akita N; Hattori H; Maeda N; Horibe K
    Leuk Lymphoma; 2014 Jul; 55(7):1652-3. PubMed ID: 24024475
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting cancer with small molecule kinase inhibitors.
    Zhang J; Yang PL; Gray NS
    Nat Rev Cancer; 2009 Jan; 9(1):28-39. PubMed ID: 19104514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib Mesylate.
    Waller CF
    Recent Results Cancer Res; 2018; 212():1-27. PubMed ID: 30069623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precision Deuteration in Search of Anticancer Agents: Approaches to Cancer Drug Discovery.
    Mourya A; Prajapati N
    Cancer Biother Radiopharm; 2024 Feb; 39(1):1-18. PubMed ID: 37585602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
    Mohammadi M; Gelderblom H
    Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 35.